JASERV

What JASERV does

JASERV SRL is an Italian healthcare technology company founded in 2022 and headquartered in Quartu Sant'Elena, Sardinia. The company develops automated and semi-automated systems for pharmaceutical compounding in hospital pharmacies, addressing the manual and error-prone process of preparing personalized galenic magistral preparations. Its target end users are hospital pharmacies and healthcare facilities, where sterility, dosing accuracy, and traceability of personalized medications are operational and regulatory priorities.

Its core product platform, NILA, comprises two devices: NILA MD, a semi-automatic compounding system, and NILA CLUSTER, a fully automatic multi-module configuration. The technology integrates gravimetric sensors, peristaltic pumps, software automation, and robotics. A notable technical capability is the handling of glass ampoules per the ISO DIN 9187 standard — typically a manual breaking process — combined with features such as RFID and biometric authentication, real-time gravimetric dosing, dose quadruplication, and gravimetric dilution of powdered medications. A patent application has been filed under Work Package 5 of the development plan, and CE marking is in progress.

JASERV is pre-revenue and pre-commercialization. The company operates within a POR FESR 2014-2020 Voucher Startup project with a total budget of €100,000 (€79,000 grant funded) running from November 8, 2022 to November 4, 2024. The intended business model is the sale or placement of compounding devices into hospital pharmacies, with revenue mechanics and pricing not yet disclosed.

Name

JASERV

Legal name

Jaserv srl

Website

https://jaserv.com

Company type

Private

Founded year

2022

Operating status

Operating

Short description

JASERV SRL is an Italian healthcare technology startup that develops the NILA platform — automated and semi-automatic compounding systems for hospital pharmacies preparing galenic magistral preparations, with capabilities including glass ampoule handling and gravimetric dosing.

Ownership category

akta.pro rank

Product category

Hospital Pharmacy Automation

NAICS

Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Compounding & Customized Medication Management Support (HSABALAL)

akta.pro secondary industry

Specialty Pharmacy & Complex Therapy Management Platforms (HLACAKAG)

Keywords

• Automated pharmaceutical compounding
• Hospital pharmacy automation
• Galenic magistral preparation
• Gravimetric dosing systems
• Medical device robotics

Headquarters

HQ city

Quartu Sant'elena

HQ country

Italy

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain

Revenue model

1. Automated Compounding Devices: Sale of automated and semi-automated devices (NILA MD, NILA CLUSTER) for galenic magistral preparation. The company manufactures and commercializes autonomous modular systems for preparing a wide range of medicinal specialties.
2. Accessories and Customization: Sale of accessory kits for final container customization and standard commercial kits (Luer-lock extensions and needles).
3. Pilot Validation Services: Validation, certification, and installation services at pilot center (Work Package 7).

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

JASERV designs, manufactures, and commercializes the NILA platform of autonomous modular devices (NILA MD semi-automatic and NILA CLUSTER fully automatic) for hospital pharmacy compounding of galenic magistral preparations, including antibiotics, supportive therapies, and antitumor drugs for parenteral administration. The systems combine real-time gravimetric sensing, robotic control of peristaltic pumps, automatic reconstitution and dose squaring, multi-container packaging handling (including unique glass ampoule support), and full traceability with advanced operator authentication.

Product overview

JASERV offers the NILA platform for automated and semi-automated preparation of galenic magistral therapies. The portfolio consists of two product variants: NILA MD (semi-automatic) and NILA CLUSTER (fully automatic, multi-module parallel configuration). Both products handle reconstitution, gravimetric dilution, and dose preparation for antibiotics, supportive therapies, and anti-tumor medications in glass vials and vials with ISO20/ISO13 packaging, outputting to various hospital containers (Ecoflac, infusion bags, elastomeric pumps, syringes). The semi-automatic NILA MD targets individual preparation workflows while the NILA CLUSTER enables high-capacity centralized production through coordinated parallel modules.

Differentiator

Problem solved

Functional benefit

Brands

• NILA MD: Automatic apparatus for preparing galenic magistral therapies, including antibiotics, support therapies, and anti-tumor treatments for parenteral administration. Available in semi-automatic version (NILA MD) or automatic cluster configuration (NILA CLUSTER).
• NILA CLUSTER

Products and services

• NILA MD NILA MD is a semi-automatic compact apparatus (module footprint LxHxP 300x600x300 mm) for the preparation of galenic magistral therapies, including antibiotics, supportive therapies such as corticosteroids and antiemetics, and antitumor drugs for parenteral administration (intravenous/bolus). It automatically reconstitutes powdered medicinal specialties, performs gravimetric dilution and automatic dose squaring, handles vials (ISO20/ISO13) and glass ampoules (ISO DIN 9187), and packages the final product into Ecoflac, infusion bags, elastomeric pumps, syringes, and other hospital containers. It targets hospital pharmacy departments seeking automated compounding with a smaller footprint and lower cost than fully robotic systems.
• NILA CLUSTER NILA CLUSTER is the fully automatic version of the NILA system, comprising multiple coordinated modules working in parallel to enable higher-throughput and centralized galenic magistral compounding across multiple hospital wards and departments. It combines real-time gravimetric dosing, automatic reconstitution and dose squaring, multi-container packaging, glass ampoule handling, and full operation traceability with advanced authentication for hospital pharmacy production environments.
• NILA Accessory Kits and Standard Commercial Kits Accessory kits enabling customization of the final container (Ecoflac, infusion bags, elastomeric pumps, syringes) on the NILA platform, together with standard commercial kits comprising luer-lock extensions and needles. Designed for hospital pharmacies deploying NILA MD or NILA CLUSTER systems.
• Pilot Validation, Certification and Installation Services Professional services covering on-site validation, CE certification support, and installation of NILA automated compounding systems at the designated pilot healthcare center, as part of field readiness and regulatory compliance activities. Targeted at hospital pharmacies and healthcare facilities adopting the NILA platform.

Quantifiable outcome

• Drastic reduction in therapeutic errors through automated dose calculation and verification
• +3 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Two partnerships are on record, tiered minor and core.

• Sardegna RicercheminorStrategic or Co-development PartnerRegional research entity co-referenced in Voucher Startup program context, potentially supporting innovation ecosystem connections.
• Pilot CentercoreStrategic or Co-development PartnerHealthcare facility designated for field validation, certification, and installation of the NILA system (Work Package 7). Critical for CE marking and real-world testing.

Scale indicators2 records

Recent moves4 records

Expansion highlights3 records

Broad incumbents

• Omnicell: US-listed leader in medication management and pharmacy automation, with IV compounding solutions as part of its broader hospital pharmacy offering. Overlaps with JASERV on automated parenteral preparation but at vastly larger scale and breadth.
• ICU Medical: Global medical device company with a portfolio in IV therapy, including compounding and infusion systems. Competes with JASERV in the broader hospital IV preparation workflow, though ICU Medical's strength is in infusion sets and connectors rather than compounding robots specifically.
• Grifols: Spanish global healthcare company with growing presence in hospital pharmacy automation via its KIRO Oncology acquisition. Competes with JASERV across the broader compounding and plasma-derived therapy value chain.
• B. Braun: Large German medical technology and pharmaceutical company offering IV solutions, infusion devices, and pharmacy compounding products. Competes with JASERV in hospital pharmacy automation as part of a much broader medtech portfolio.
• Baxter International: Global hospital products company with strong positions in IV solutions, infusion pumps, and pharmacy compounding. Competitor in the hospital parenteral preparation space, though JASERV's focus on galenic magistral compounding addresses a narrower workflow.

Emerging players

• ARxIUM: North American pharmacy automation vendor with IV compounding and packaging solutions. Comparable to JASERV as a focused automation player targeting hospital pharmacy compounding workflows, though operating at greater scale and primarily in the US/Canada.
• Health Robotics (now part of Omnicell): Originally an Italian-founded vendor of IV compounding robots for hazardous drugs, now part of Omnicell. Comparable to JASERV as a focused automated compounding player with European roots and hospital pharmacy orientation.

Direct peers

• Newicon: Finnish vendor of pharmacy automation including IV compounding and dispensing systems for hospital and retail pharmacies. Directly comparable to JASERV in targeting automated parenteral preparation workflows for European hospital pharmacies.
• Loccioni (Apoteca): Italian engineering group with the Apoteca line of automated IV compounding robots for hospital pharmacies. Direct peer given shared Italian footprint, hospital pharmacy customer base, and focus on automated galenic/non-sterile-to-sterile compounding.
• KIRO Oncology (Grifols): KIRO Oncology, now part of Grifols, manufactures robotic IV compounding systems for hospital pharmacies — most notably for hazardous antitumor drug preparation. It is the closest direct competitor to JASERV's NILA, targeting the same hospital pharmacy customer with automated parenteral compounding.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about JASERV